Treatment of frozen shoulder with hyaluronic acid injections
Efficacy of Intra-articular Hyaluronate Injection for Adhesive Capsulitis
This study is testing if hyaluronic acid injections can help people with frozen shoulder feel less pain and move their shoulder better.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 40 Years to 70 Years |
| Sex | All |
| Sponsor | Tri-Service General Hospital Academic / other |
| Locations | 1 site (Taipei, Alberta) |
| Trial ID | NCT05983081 on ClinicalTrials.gov |
What this trial studies
This clinical trial evaluates the effectiveness of intra-articular hyaluronic acid (HA) injections for patients suffering from adhesive capsulitis, commonly known as frozen shoulder. The study is designed as a prospective, case-controlled trial conducted in the rehabilitation department of a medical center. A total of 30 participants will receive 60mg of HA injected into the glenohumeral joint once a week for three consecutive weeks, with assessments of shoulder range of motion and pain levels conducted at multiple intervals post-treatment.
Who should consider this trial
Good fit: Ideal candidates are individuals aged 40 to 70 diagnosed with frozen shoulder, experiencing restricted shoulder movement but with a pain score of less than 3.
Not a fit: Patients with full-thickness rotator cuff tears, systemic rheumatic diseases, or a history of shoulder fractures or surgeries may not benefit from this treatment.
Why it matters
Potential benefit: If successful, this treatment could significantly improve shoulder mobility and reduce pain for patients with adhesive capsulitis.
How similar studies have performed: Other studies have shown promising results with hyaluronic acid injections for similar conditions, suggesting potential efficacy.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: A. Patients diagnosed with frozen shoulder by a clinical physician based on the patient's medical history, physical examination, X-ray, and ultrasound or magnetic resonance imaging reports. B. Clinical course: Patients must have a pain score of less than 3, no nighttime shoulder pain, and be in the post-freezing stage, primarily presenting restricted shoulder joint range of motion. C. The affected shoulder joint must have at least two angles of shoulder joint movement reduced by at least 30% compared to the healthy side: shoulder flexion, abduction, and external rotation, or a single affected side abduction angle reduced by 50% relative to the healthy side. D. Age between 40 to 70 years old. - Exclusion Criteria: A. full-thickness tear or massive tear of the rotator cuff tendons or calcific tendinitis. B. Presence of systemic rheumatic disease. C. History of shoulder fracture or previous shoulder surgery. D. Received shoulder injections for treatment within the last 3 months. E. Acute cervical nerve root compression. F. Current pregnancy or lactation. G. Patients with shoulder instability or cancer. H. Patients with cognitive impairment, unable to follow simple instructions, or unable to comply with the study procedures.
Where this trial is running
Taipei, Alberta
- Tri-Service General Hospital — Taipei, Alberta, Taiwan (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.